BioNTech SE
BNTX
$107.34
-$0.16-0.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -258.18% | 27.01% | 125.05% | -154.18% | -169.39% |
| Total Depreciation and Amortization | -74.45% | 261.20% | -9.12% | 29.18% | -50.99% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 104.43% | 7.84% | -1,185.11% | 107.31% | -301.83% |
| Change in Net Operating Assets | 40.61% | 0.60% | -129.16% | 954.18% | 22.74% |
| Cash from Operations | -66.36% | 29.69% | -140.10% | 608.46% | -137.60% |
| Capital Expenditure | 27.51% | 11.30% | 16.07% | -50.16% | 29.52% |
| Sale of Property, Plant, and Equipment | -29.48% | 126.26% | 53.18% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 101.63% | 1,037.01% | 53.54% | 93.25% | 13.28% |
| Cash from Investing | 102.88% | 513.98% | 39.87% | 89.61% | 13.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -89.04% | 7.59% | 65.50% | -193.59% | 36.59% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -86.62% | 10.40% | 64.76% | -191.09% | 39.03% |
| Foreign Exchange rate Adjustments | -216.87% | 673.33% | 28.81% | -148.12% | 104.90% |
| Miscellaneous Cash Flow Adjustments | -5.09% | -130.75% | -1.39% | 162.35% | -139.40% |
| Net Change in Cash | 204.15% | 117.70% | -154.87% | 151.66% | -47.89% |